Augmedix–Google-Glass” class=”halfright” src=”https://www.medicaldevice-network.com/wp-content/uploads/image-digitalinsightresearch/Archive/nri/medicaldevice/news/MD/Augmedix-Google-Glass.JPG” />
The proceeds will be used by Ray Vio to increase its production of UV disinfection products for both water and air to meet the global demand, to expand its manufacturing capacity, to increase its staff, and also to expand its distribution channels, application support, and expand sales and marketing capabilities across the world.
AnthroTronix, a R&D company that develops health technology, has partnered with Pelion, a Polish pharmaceutical distributor, to form a new joint venture (JV) company named DANA Brain Vital Europe LTD.
The two JV partners hold an equal share in the new company, which will develop products based on the DANA platform. The new products will be marketed under Pelion’s brand name ‘CogniNET’ in Europe.
DANA is a mobile medical app approved by the US FDA in October 2014. Designed with a series of game-like tests, the app assesses and measures a person’s brain / cognitive health within minutes. The app will help clinicians to track cognitive function during treatment for depression, dementia / Alzheimer’s disease, and post-traumatic stress disorder (PTSD).
Augmedix, the first and largest Google Glass start-up that provides health record documentation services, has secured a $17m strategic investment through venture financing.
Led by Redmile Group, the strategic round of funding involved investments from leading US healthcare companies Sutter Health, Dignity Health, Catholic Health Initiatives (Chi), TriHealth, and founding institutional investors Emergence Capital Partners and DCM Ventures.
The funds will be used by Augmedix to expand its Google Glass-powered service to health systems, hospitals and private clinics across the US.
ChartSpan Medical Technologies, a healthcare technology company based in South Carolina, has raised $3.2m from a syndicate of investors based in Texas. The latest venture financing round brings the company’s total funding to $6m.
Proceeds from the funding will be used to expand ChartSpan’s operations and to hire more than 300 clinical and technology staff within a year.
The agreement enables Integra to gain access to acellular dermal matrices derived from donated human dermis. The company will market the matrices under the brand HuMend Acellular Dermal Matrix (HuMend) to offer soft tissue repair solutions for patients undergoing plastic reconstructive procedures.
HuMend is scheduled for launch in mid-2016 across North America.
Image: A Google Glass headset. Photo: courtesy of AUGMEDIX, INC.